Imaging for early stage breast cancer

Risk factors: after lumpect. + WBRT +/- boost

Fig 2. HR 10-y recurrences, specified for trastuzumab use in luminal B/HER2.

Van Maaren M et al. Int J Cancer 2018, doi: 10.1002/ijc.31914.